NEXM Nexmed (MM)

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalency in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

NexMed conducted two pre-clinical studies on its NexACT-based topical psoriasis treatment. The first efficacy study using a cadaver skin model showed that the NexACT-based formulation of the two active drugs delivered the same level of drugs (measured in ug/cm2/hour) as compared to the commercial Talconex® product. In a second efficacy study, using the DNFB induced allergic contact dermatitis (ACD) pig model, results showed that the NexACT-based formulation significantly lowered the clinical inflammation and erythema score in sick animals. The DNFB induced ACD pig model is the standard pre-clinical model for testing efficacy of calcipotriene-based drugs for psoriasis treatments under development.

Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, stated, “We have a competitive psoriasis treatment under development. Our NexACT-based formulation is novel and does not infringe on the marketed topical treatments. Our data, though early stage, shows bioequivalency to Talconex®, and further supports the versatility of the NexACT technology and its applicability to a broad range of disease states. We look forward to commencing partnering discussions for continued development of this product candidate.”

About Psoriasis

Psoriasis is a chronic autoimmune disease that appears on the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. There are five types of psoriasis: plaque, guttate, inverse, pustular and erythrodermic. The most common form, plaque psoriasis, appears as raised, red patches or lesions covered with a silvery white buildup of dead skin cells, called scale. Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes, heart disease and depression. According to the National Institutes of Health, as many as 7.5 million Americans and 125 million people worldwide, have psoriasis.

About NexMed, Inc.

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT® drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including but not limited to its ability to replicate pre-clinical results in human clinical trials, whether its product candidates infringe on third party rights, and whether the it can successfully partner product candidates.

Nexmed (MM) (NASDAQ:NEXM)
過去 株価チャート
から 5 2024 まで 6 2024

Nexmed (MM) (NASDAQ:NEXM)
過去 株価チャート
から 6 2023 まで 6 2024